ArticleAJO international2026
Recorded ocular diagnoses in adults with homocystinuria: A propensity score-matched cohort study.
Article in AJO international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Purpose: To compare ocular diagnoses in adults with and without homocystinuria (HCU), including vitreous degeneration in a large, real-world cohort. Design: Retrospective propensity score-matched cohort study. Participants: 658 adults with HCU and 658 propensity score-matched controls without HCU. Methods: Using the U.S. TriNetX Research Network, patients with HCU were matched to controls by demographic characteristics and systemic comorbidities associated with ocular disease. Outcomes included cataract, glaucoma, dry eye disease, vitreous degeneration, myopia, and age-related macular degeneration. Patients with the corresponding diagnosis before the ophthalmic index encounter were excluded from primary time-to-event analyses. Cox models estimated hazard ratios (HRs); log-rank P values were Holm-adjusted across six outcomes. A secondary analysis included diagnoses recorded before or after index. Results: Vitreous degeneration was recorded after index in 45/581 patients with HCU (7.75%) and 29/607 controls (4.78%). HCU was associated with a higher risk of first recorded vitreous degeneration (HR, 1.77; 95% CI, 1.11-2.82; nominal Conclusion: HCU was associated with a higher risk of vitreous degeneration, but the primary association did not remain significant after multiplicity correction. Prospective studies using standardized ophthalmic assessments are needed to determine whether this signal represents a reproducible HCU-related vitreous phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.